Thomas Suedhof - Sanofi Independent Director
| SNYNF Stock | USD 95.54 1.54 1.64% |
Director
Dr. Thomas Suedhof has served as Independent Director of Sanofi S.A. since May 2016. He is Chairman of the Scientific Committee of the Company. He holds a Medical Degree from the GeorgAugustUniversitaet Goettingen and a Medical Degree from Aachen University . He is the Avram Goldstein Professor in the School of Medicine of Stanford University, as well as a Professor of Molecular Cellular Physiology, Psychiatry, and Neurology. Prior to this position, he spent 25 years at the University of Texas, Southwestern, where he acted as Chairman of the Department of Neuroscience. Most of his research at that time focused on the mechanisms of synaptic information transmission which have pharmacological consequences for the treatment of neurodegenerative and neuropsychiatric diseases. He won the Nobel Prize in Physiology or Medicine in 2013, the Albert Lasker Medical Basic Research Award together with Richard Scheller, as well as the Bernhard Katz Award of the Biophysical Society . since 2016.
| Age | 62 |
| Tenure | 8 years |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi Management Efficiency
The company has return on total asset (ROA) of 0.0607 % which means that it generated a profit of $0.0607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0959 %, meaning that it generated $0.0959 on every $100 dollars invested by stockholders. Sanofi's management efficiency ratios could be used to measure how well Sanofi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Eckert | Amgen Inc | 63 | |
| Inge Thulin | Merck Company | 67 | |
| Mary Coe | Merck Company | 54 | |
| Etienne Davignon | Gilead Sciences | 82 | |
| Christine Seidman | Merck Company | 68 | |
| David Baltimore | Amgen Inc | 78 | |
| Francois Carbonnel | Amgen Inc | 69 | |
| Robert Williams | Amgen Inc | 69 | |
| Deryck Maughan | GlaxoSmithKline PLC ADR | 66 | |
| John Madigan | Gilead Sciences | 77 | |
| Hans Wijers | GlaxoSmithKline PLC ADR | 64 | |
| Tyler Jacks | Amgen Inc | 57 | |
| John Cogan | Gilead Sciences | 70 | |
| Charles Bancroft | GlaxoSmithKline PLC ADR | 61 | |
| Pierre Landolt | Novartis AG ADR | 70 | |
| Paul Rothman | Merck Company | 63 | |
| Rebecca Henderson | Amgen Inc | 57 | |
| Craig Thompson | Merck Company | 64 | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
| Marvinder Banga | GlaxoSmithKline PLC ADR | 66 | |
| Kathy Warden | Merck Company | 49 | |
Management Performance
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 |
Sanofi Leadership Team
Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
| Emmanuel Babeau, Independent Director | ||
| Roy Papatheodorou, Gen VP | ||
| Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
| Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
| Dieter Weinand, Executive Vice President Member of the Executive Board | ||
| Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
| Eva SchaeferJansen, Head Relations | ||
| Fabienne Lecorvaisier, Director | ||
| George Grofik, Vice President of Investor Relations | ||
| Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel | ||
| Klaus Pohle, Independent Director | ||
| John Reed, President - Global Research & Development, Member of the Executive Committee | ||
| Bernard Charles, Independent Director | ||
| Melanie Lee, Independent Director | ||
| Pierre Chancel, Sr Marketing | ||
| Christophe Babule, Director | ||
| Bonnie Bassler, Director | ||
| Thomas Suedhof, Independent Director | ||
| Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
| Laurent Attal, Director | ||
| JeanRene Fourtou, Independent Director | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Christian Mulliez, Director | ||
| Robert Castaigne, Independent Director | ||
| Laurent Gilhodes, Principal Accounting | ||
| Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
| Uwe Bicker, Independent Director | ||
| Josep Catlla, Head Communications | ||
| Claudie Haignere, Independent Director | ||
| Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
| Paul Hudson, CEO Director | ||
| Bruno Mnard, Chief officer | ||
| Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
| Dante Beccaria, Global VP | ||
| Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
| William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
| Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
| David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
| Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
| Diane Souza, Independent Director | ||
| Carole Piwnica, Independent Director | ||
| Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
| Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
| Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
| Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
| DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
| Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
| Igor Landau, Director | ||
| Patrick Kron, Independent Director | ||
| Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
| Gerard Kemmel, Independent Director | ||
| SuetFern Lee, Independent Director | ||
| Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
| David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
| Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
| Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 135.37 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 11.23 % | |||
| Shares Owned By Institutions | 46.69 % | |||
| Price To Earning | 7.73 X | |||
| Price To Book | 1.60 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sanofi in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sanofi's short interest history, or implied volatility extrapolated from Sanofi options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Sanofi Pink Sheet analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |